Neoleukin Therapeutics (NLTX) Short Interest Ratio & Short Volume → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Free NLTX Stock Alerts $37.16 -0.31 (-0.83%) (As of 06/6/2024 ET) Add Compare Share Share Short InterestStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends Neoleukin Therapeutics Short Interest DataCurrent Short Interest26,400 sharesPrevious Short Interest27,500 sharesChange Vs. Previous Month-4.00%Dollar Volume Sold Short$91,344.00Short Interest Ratio1.1 Days to CoverLast Record DateNovember 30, 2023Outstanding Shares9,398,000 sharesFloat Size7,440,000 sharesShort Percent of Float0.35%Today's Trading Volume65,948 sharesAverage Trading Volume50,104 sharesToday's Volume Vs. Average132% Short Selling Neoleukin Therapeutics ? Sign up to receive the latest short interest report for Neoleukin Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartNLTX Short Interest Over TimeNLTX Days to Cover Over TimeNLTX Percentage of Float Shorted Over Time Ad HedgeyeNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analysis meets hedge fund-level market foresight!TRY "INVESTING IDEAS" TODAY Neoleukin Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/202326,400 shares $91,344.00 -4.0%0.4%1.1 $3.46 11/15/202327,500 shares $94,875.00 -20.1%0.4%1.2 $3.45 10/31/202334,400 shares $116,272.00 -23.4%0.5%1 $3.38 10/15/202344,900 shares $162,089.00 -8.0%0.6%1.1 $3.61 9/30/202348,800 shares $192,760.00 +13.5%0.7%0.8 $3.95 9/15/202343,000 shares $161,250.00 -63.5%0.1%0.7 $3.75 Get the Latest News and Ratings for NLTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Neoleukin Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/31/2023117,900 shares $88,778.70 -7.9%0.3%0.4 $0.75 8/15/2023128,000 shares $85,760.00 -28.1%0.4%0.5 $0.67 7/31/2023178,000 shares $122,820.00 -20.1%0.5%0.8 $0.69 7/15/2023222,900 shares $196,152.00 -1.7%0.6%1 $0.88 6/30/2023226,700 shares $188,161.00 +7.4%0.7%1.8 $0.83 6/15/2023211,100 shares $156,214.00 -8.1%0.6%1.3 $0.74 5/31/2023229,600 shares $183,680.00 -7.5%0.7%0.6 $0.80 5/15/2023248,300 shares $214,779.50 -18.5%0.7%0.6 $0.87 4/30/2023304,700 shares $272,523.68 -15.7%0.8%0.7 $0.89 4/15/2023361,400 shares $285,506.00 -37.7%1.0%0.9 $0.79 3/31/2023580,000 shares $406,000.00 -0.7%1.7%1.5 $0.70 3/15/2023584,100 shares $362,142.00 +143.8%1.7%1.4 $0.62 2/28/2023239,600 shares $120,638.60 -26.4%0.7%0.6 $0.50 2/15/2023325,400 shares $191,986.00 +26.1%1.0%1.4 $0.59 1/31/2023258,100 shares $153,595.31 +9.8%0.8%0.9 $0.60 1/15/2023235,000 shares $137,193.00 -14.8%0.7%0.8 $0.58 12/30/2022275,800 shares $140,382.20 -31.3%0.8%1 $0.51 12/15/2022401,600 shares $181,764.16 -26.2%1.2%1.6 $0.45 11/30/2022543,800 shares $277,338.00 +14.6%1.6%3 $0.51 11/15/2022474,500 shares $201,567.60 +21.1%1.4%2.6 $0.42 10/31/2022391,700 shares $222,642.28 +10.6%1.2%1.8 $0.57 10/15/2022354,300 shares $209,603.88 -5.2%1.1%1.6 $0.59 9/30/2022373,800 shares $239,232.00 -30.1%1.1%1.6 $0.64 9/15/2022534,700 shares $540,047.00 -27.2%1.6%1.7 $1.01 8/31/2022734,500 shares $756,535.00 -35.6%2.2%2.2 $1.03 8/15/20221,140,000 shares $1.35 million +17.7%3.4%3.1 $1.18 7/31/2022968,300 shares $977,983.00 -6.0%2.9%3.1 $1.01 7/15/20221,030,000 shares $1.11 million -2.8%3.1%3.2 $1.08 6/30/20221,060,000 shares $1.09 million -52.5%3.2%2.9 $1.03 6/15/20222,230,000 shares $2.17 million -0.5%6.7%5.8 $0.97 5/31/20222,240,000 shares $2.24 million +6.2%6.7%7.1 $1.00 5/15/20222,110,000 shares $2.07 million +11.1%6.3%7.4 $0.98 4/30/20221,900,000 shares $2.32 million +22.6%5.7%7.2 $1.22 4/15/20221,550,000 shares $2.14 million +2.0%4.6%5.7 $1.38A New Generation of Billionaires Is About to Be Created (Ad)On June 30, AI will hit a tipping-point… $15.7 trillion of wealth is at stake. As many as 800 million jobs are caught in AI’s crosshairs…Click here for details. 3/31/20221,520,000 shares $2.86 million +8.6%4.6%6.4 $1.88 3/15/20221,400,000 shares $2.63 million +2.9%4.2%6.4 $1.88 2/28/20221,360,000 shares $3.51 million +7.9%4.1%6.8 $2.58 2/15/20221,260,000 shares $3.68 million +9.6%3.8%5.7 $2.92 1/31/20221,150,000 shares $4.11 million +23.3%3.7%4.9 $3.57 1/15/2022932,400 shares $3.57 million +21.6%2.9%4.4 $3.83 12/31/2021767,000 shares $3.70 million +3.7%2.3%4 $4.82 12/15/2021739,600 shares $3.62 million -14.8%2.3%4.2 $4.90 11/30/2021867,800 shares $4.65 million +3.8%2.7%4.7 $5.36 11/15/2021836,100 shares $5.24 million -47.4%2.6%4.2 $6.27 10/29/20211,590,000 shares $11.65 million +4.6%4.9%9 $7.33 10/15/20211,520,000 shares $10.97 million -9.0%4.6%7.8 $7.22 9/30/20211,670,000 shares $12.07 million -15.7%5.1%8.5 $7.23 9/15/20211,980,000 shares $15.92 million +4.8%6.0%9 $8.04 8/31/20211,890,000 shares $15.40 million -6.9%5.8%8.6 $8.15 8/13/20212,030,000 shares $13.82 million -2.9%6.2%10.8 $6.81 7/30/20212,090,000 shares $14.61 million +1.5%6.4%11.1 $6.99 7/15/20212,060,000 shares $17.22 million No Change6.3%11.7 $8.36 6/30/20212,060,000 shares $19.01 million -21.4%6.3%11.3 $9.23 6/15/20212,620,000 shares $26.83 million -4.7%8.0%14.5 $10.24 5/28/20212,750,000 shares $27.58 million -5.5%8.4%14.6 $10.03 5/14/20212,910,000 shares $30.23 million +2.5%N/A15.6 $10.39 4/30/20212,840,000 shares $36.89 million +5.2%N/A13.9 $12.99 4/15/20212,700,000 shares $32.81 million -19.6%N/A12.7 $12.15 3/31/20213,360,000 shares $40.19 million +2.4%N/A13.6 $11.96 3/15/20213,280,000 shares $39.16 million +10.1%N/A7.9 $11.94 2/26/20212,980,000 shares $37.04 million -7.5%N/A7.5 $12.43 2/12/20213,220,000 shares $41.18 million +7.7%N/A8.1 $12.79 1/29/20212,990,000 shares $37.70 million -1.3%N/A7.4 $12.61 1/15/20213,030,000 shares $40.21 million +1.0%N/A7.7 $13.27 12/31/20203,000,000 shares $42.96 million +37.0%N/A7.8 $14.32 12/15/20202,190,000 shares $27.59 million -2.2%N/A6.6 $12.60 11/30/20202,240,000 shares $30.13 million -6.7%N/A11.3 $13.45 11/15/20202,400,000 shares $30.60 million -5.9%N/A12 $12.75 10/30/20202,550,000 shares $27.64 million +1.6%N/A12.6 $10.84 10/15/20202,510,000 shares $29.77 million -2.0%N/A11.1 $11.86 9/30/20202,560,000 shares $30.72 million -3.8%N/A10.5 $12.00 9/15/20202,660,000 shares $33.81 million -2.6%N/A6.5 $12.71 8/31/20202,730,000 shares $34.70 million -15.5%N/A6 $12.71 8/14/20203,230,000 shares $39.70 million +1.3%N/A6.9 $12.29 7/31/20203,190,000 shares $30.88 million +4.3%N/A7 $9.68 7/15/20203,060,000 shares $34.03 million -8.9%N/A6.9 $11.12 6/30/20203,360,000 shares $55.78 million +44.2%N/A7.6 $16.60 6/15/20202,330,000 shares $29.47 million +7.4%N/A7.7 $12.65 5/29/20202,170,000 shares $26.26 million +2.4%N/A7.8 $12.10 5/15/20202,120,000 shares $27.56 million +6.0%N/A7.7 $13.00 4/30/20202,000,000 shares $22.28 million +22.7%N/A6.9 $11.14 4/15/20201,630,000 shares $20.33 million +3.2%N/A5.3 $12.47 3/31/20201,580,000 shares $19.80 million -3.5%N/A4.5 $12.53 3/13/20201,638,000 shares $18.59 million +13.0%N/A6.6 $11.35A New Generation of Billionaires Is About to Be Created (Ad)On June 30, AI will hit a tipping-point… $15.7 trillion of wealth is at stake. As many as 800 million jobs are caught in AI’s crosshairs…Click here for details. 2/28/20201,450,000 shares $13.18 million +20.8%N/A2.4 $9.09 2/14/20201,200,000 shares $10.10 million +0.8%N/A1.9 $8.42 1/31/20201,190,000 shares $11.90 million +35.0%N/A2 $10.00 1/15/2020881,400 shares $10.48 million +60.7%N/A1.6 $11.89 12/31/2019548,400 shares $5.81 million -17.3%N/A1.1 $10.60 9/15/201969,500 shares $219,620.00 +167.3%0.3%0.4 $3.16 NLTX Short Interest - Frequently Asked Questions What is Neoleukin Therapeutics' current short interest? Short interest is the volume of Neoleukin Therapeutics shares that have been sold short but have not yet been covered or closed out. As of November 30th, investors have sold 26,400 shares of NLTX short. 0.35% of Neoleukin Therapeutics' shares are currently sold short. Learn More on Neoleukin Therapeutics' current short interest. What is a good short interest ratio for Neoleukin Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NLTX shares currently have a short interest ratio of 1.0. Learn More on Neoleukin Therapeutics's short interest ratio. What is a good short interest percentage for Neoleukin Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.35% of Neoleukin Therapeutics' floating shares are currently sold short. Is Neoleukin Therapeutics' short interest increasing or decreasing? Neoleukin Therapeutics saw a decrease in short interest during the month of November. As of November 30th, there was short interest totaling 26,400 shares, a decrease of 4.0% from the previous total of 27,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Neoleukin Therapeutics' float size? Neoleukin Therapeutics currently has issued a total of 9,398,000 shares. Some of Neoleukin Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Neoleukin Therapeutics currently has a public float of 7,440,000 shares. How does Neoleukin Therapeutics' short interest compare to its competitors? 0.35% of Neoleukin Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Neoleukin Therapeutics: Organogenesis Holdings Inc. (14.60%), XBiotech Inc. (3.65%), SIGA Technologies, Inc. (12.36%), Relmada Therapeutics, Inc. (5.20%), Spyre Therapeutics, Inc. (12.85%), Kiniksa Pharmaceuticals, Ltd. (5.62%), ANI Pharmaceuticals, Inc. (0.97%), Akero Therapeutics, Inc. (12.05%), MannKind Co. (13.13%), Mirum Pharmaceuticals, Inc. (18.69%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: RTX Co. ($6.17 billion), Canadian Natural Resources Limited ($3.99 billion), T-Mobile US, Inc. ($3.78 billion), Charter Communications, Inc. ($3.37 billion), Coinbase Global, Inc. ($2.89 billion), Suncor Energy Inc. ($2.83 billion), Occidental Petroleum Co. ($2.64 billion), Tractor Supply ($2.31 billion), Royal Caribbean Cruises Ltd. ($1.73 billion), and Rivian Automotive, Inc. ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Neoleukin Therapeutics stock? Short selling NLTX is an investing strategy that aims to generate trading profit from Neoleukin Therapeutics as its price is falling. NLTX shares are trading down $0.31 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Neoleukin Therapeutics? A short squeeze for Neoleukin Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of NLTX, which in turn drives the price of the stock up even further. How often is Neoleukin Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NLTX, twice per month. The most recent reporting period available is November, 30 2023. More Short Interest Resources from MarketBeat Related Companies: ORGO Short Squeeze XBIT Short Squeeze SIGA Short Squeeze RLMD Short Squeeze SYRE Short Squeeze KNSA Short Squeeze ANIP Short Squeeze AKRO Short Squeeze MNKD Short Squeeze MIRM Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:NLTX) was last updated on 6/7/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredProtect Your Bank Account Before It’s Too LateFor months I’ve been warning about the federal government’s terrifying new program to control every American’s...Weiss Ratings | SponsoredAlert: Your Bank is Dying – Act Now or Lose Everything!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put...Priority Gold | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neoleukin Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neoleukin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.